BC Innovations | Nov 18, 2019
Distillery Therapeutics

The transcription factors ID1 and ID3 as targets for AMD and retinopathy

DISEASE CATEGORY: Ophthalmic INDICATION: Age-related macular degeneration (AMD); retinopathy of prematurity A Memorial Sloan Kettering Cancer Center team led by Angiogenex Inc. CEO Robert Benezra showed that inhibiting the transcription factors ID1 and ID3 could...
BC Innovations | May 30, 2018
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest promoting expression of the miR-371-373 cluster encoding miR-371, miR-372 and miR-373 or inhibiting the TGFβ-RII/ID1 axis could help treat colorectal cancer. In colorectal cancer...
BC Innovations | May 14, 2015
Distillery Therapeutics

Therapeutics: Inhibitor of DNA binding 1 (ID1)

Cancer INDICATION: Cancer Studies in patients and mice suggest inhibiting ID1 could help treat cancer. In peripheral blood monocytes from patients with metastatic breast cancer or metastatic melanoma, ID1 levels were higher than in monocytes...
BC Innovations | May 14, 2015
Translation in Brief

Check Your ID

A new pathway of immune suppression has been uncovered in a joint study by Regeneron Pharmaceuticals Inc. and researchers at Weill Cornell Medical College that positions inhibitor of DNA binding 1 (ID1) as a key...
BC Innovations | May 15, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Activin receptor-like kinase 2 (ALK2; ACVR1); SMAD family member 1 (MADH1; SMAD1); inhibitor of DNA binding 1 (ID1) Three studies in primary tumors...
BC Week In Review | Mar 3, 2014
Clinical News

AngioGenex preclinical data

In a mouse model of breast cancer, twice-daily AGX-51 significantly blocked tumor growth at a dose <7 mg/kg when given in combination with a taxane and completely blocked tumor-associated angiogenesis when given alone at a...
BC Innovations | Dec 19, 2013
Targets & Mechanisms

Balancing act in liver fibrosis

CXCR7 , one of the few chemokine receptors against which there are virtually no drug development efforts, may be a novel target for liver fibrosis, according to new findings from a U.S. team. 1 The results...
BC Innovations | Jan 17, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Inhibitor of DNA binding 1 (ID1) Patient sample, mouse and cell culture studies suggest inhibiting ID1 could help treat glioblastoma. In patient biopsy...
BC Innovations | Dec 2, 2010
Distillery Therapeutics

Indication: Hepatic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Hepatic Inhibitor of DNA binding 1 (ID1); VEGF receptor 2 (KDR/Flk-1; VEGFR-2) Studies in mice suggest that co-transplantation of hepatocytes...
BC Week In Review | Feb 9, 2009
Clinical News

AngioGenex preclinical data

Data from a xenograft mouse model of cancer showed that AGX-51 produced significant tumor inhibition compared with saline control at day 10 (p<0.01). Additionally, mice treated with AGX-51 plus Taxol paclitaxel from Bristol-Myers Squibb Co....
Items per page:
1 - 10 of 16